Loading…
← CockpitCompetitor Analysis › INSP Inspire Medical Systems, Inc.Open in the cockpit ↗

Inspire Medical Systems, Inc.INSPCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of an implantable neurostimulation device (Inspire) that treats obstructive sleep apnea by stimulating the airway.

Momentum strong 64
Mkt cap
$1.68B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$43.9M
20-day average traded
Fwd P/E
41.3×
forward earnings
ROIC−WACC
-6.0 pp
WACC 8.4%
Hurdle
-23 pp
Req g minus delivered
Next earnings
83 days
9 Feb 2027
Close · USD$58.11
1D-2.2%
1W-6.4%
1M-18.5%
3M-5.2%
6M+31.6%
YTD-37.0%
1Y-31.5%
ATR %4.7%
Beta1.06
52w lowhigh60.5% off high

What Inspire Medical Systems does

Maker of an implantable neurostimulation device (Inspire) that treats obstructive sleep apnea by stimulating the airway.

Sold per implant to hospitals and surgery centres, where surgeons place the pulse generator and nerve lead, so revenue follows the number of procedures, which depend on insurer approval of each patient. Sleep doctors refer patients who cannot tolerate CPAP masks, and the company trains surgeons and runs patient-marketing campaigns to feed the pipeline.

Products and services

  • Inspire upper-airway stimulation system
  • Physician training/support programs

Customers

  • Sleep medicine physicians
  • ENT surgeons
  • OSA patients

Where it sits in the supply chain

  • Medical devices
  • Sleep apnea neurostimulation
  • Implantable upper-airway stimulation…

What could go right

  • CPAP-intolerant patient population growth
  • International reimbursement expansion

What could go wrong

  • CPAP remains first-line/cheaper alternative
  • Surgeon/procedure capacity constraints

Moat: narrow (IP / patents, regulatory licence, switching costs). First and only FDA-approved implantable neurostimulator for OSA, with surgeon training lock-in.

Headquarters: Golden Valley, Minnesota · Founded: 2007 · Employees: 1,333

Named competitors

  • ResMed RMD
  • Philips PHIA.AS
  • Nyxoah SA private or unlisted
  • LivaNova LIVN
  • Fisher & Paykel Healthcare private or unlisted
  • Vivos Therapeutics private or unlisted

Inspire Medical Systems at a glance

Size Inspire Medical Systems (INSP) is a United States Health Care company (Medical Specialties) with a market value of $1.68B, the 1887th largest of 3,085 United States companies the cockpit tracks. Shares closed at $58.11 on 18 Nov 2026.

Performance Over six months the shares gained 31.6%, against -2.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 0.2% over the last twelve months (peer median +9.4%); the operating margin is 1.8% (peer median 13.6%).

Valuation It trades at 41.3× forward earnings against a peer median of 21.1× (3rd most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +51%, so the hurdle is -23 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.0 points below its cost of capital (8.4% WACC).

Short interest Short interest is 14.3% of the free float (30 Oct 2026).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026INSP 130Peer median 98
Six months, rebased to 100: Inspire Medical Systems against the median of its 20 peers (local-currency closes).

Inspire Medical Systems financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$881M$912M$803M$625M$408M
Revenue growth—+14%+28%+53%—
Gross profit$759M$779M$680M$528M$342M
EBITDA$34.4M$64.9M$42.6M-$37.4M-$44.7M
Net income$101M$145M$53.5M-$21.2M-$44.9M
Free cash flow$97.9M$78.5M$91.1M$1.02M$2.47M
Capital expenditure$37.1M$38.5M$39.1M$23.6M$9.10M
Total debt$28.6M$32.2M$31.8M$24.8M$8.87M

Quarterly statements and history in the cockpit →

Inspire Medical Systems competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%0%+20%KMTS8086XRAYEMBLA301363LMATBFLY6699301087CHEMM7716POLYMED688531VITRENOV68496880166960268AINSP6-month return →1-month return →
Up and to the right = strong over both horizons. Inspire Medical Systems is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×8086XRAYEMBLA301363LMAT6699301087CHEMM7716POLYMED688531VITRENOV6849688016INSPRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Inspire Medical Systems is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%XRAYEMBLA301363LMAT6699301087CHEMM7716VITRENOV684910666880166960268AINSPGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Inspire Medical Systems is the large dot.

Inspire Medical Systems competitors and peer comparison

Head to head with its named competitors (INSP vs RMD vs PHIA.AS vs LIVN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Inspire Medical Systems INSP$1.68B+32%0%2%41.3×28.7%
ResMed RMD$34.1B+16%+9%34%19.7×5.7%
Koninklijke Philips PHIA.AS$29.0B+17%-1%10%16.4×5.9%
LivaNova LIVN$5.21B+28%+12%15%20.9×14.2%

How Inspire Medical Systems compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Inspire Medical Systems against its 20 peers (data as of 18 Nov 2026)
MeasureINSPPeer medianRank in peer set
1-month return-18.5%-4.6%2nd lowest of 21
6-month return+31.6%-2.3%4th highest of 21
Distance from 52-week high-60.5%-24.8%3rd lowest of 21
Revenue growth (TTM)-0.2%+9.4%3rd lowest of 21
Operating margin1.8%13.6%3rd lowest of 21
Forward P/E41.3×21.1×3rd most expensive of 19
Growth the price implies (Req g, 7 yrs)28.7%11.2%most demanding of 16
Growth delivered (Del g)+51.2%+12.7%highest of 16
Hurdle (Req g minus delivered)-22.5 pp-0.6 ppleast demanding of 16
ROIC minus cost of capital-6.0 pp+0.9 pp4th lowest of 21
Net debt / EBITDA-8.7×-0.8×least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%

Questions

Who are Inspire Medical Systems's main competitors?
Named competitors: ResMed (RMD), Philips (PHIA.AS), Nyxoah SA (private or unlisted), LivaNova (LIVN), Fisher & Paykel Healthcare (private or unlisted), Vivos Therapeutics (private or unlisted). The cockpit's measured peer set (industry) also includes Kestra Medical Technologies (KMTS), NIPRO (8086.T), DENTSPLY SIRONA (XRAY), Embla Medical hf (EMBLA.CO), Mehow Innovative (301363.SZ), LeMaitre Vascular (LMAT).
Is Inspire Medical Systems expensive compared with its peers?
On forward p/e it trades at 41.3× against a peer median of 21.1×, 3rd most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +51%, so the hurdle is -23 pp: the price already allows for a slowdown.
How has Inspire Medical Systems stock performed?
Over six months to 18 Nov 2026 the shares returned +31.6% against -2.3% for the median peer; over one year -31.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.